The following addendum has been attached to the summary “Focused Update: ACC/AHA Guidelines on Peripheral Arterial Disease”:
The guideline authors reviewed all evidence available through the end of 2010. Several reports published since then have heightened doubts about the safety of varenicline, which has been associated with possible cardiovascular effects as well as with behavioral and mood effects. This evidence suggests that varenicline should be moved to the back of the clinician's arsenal of pharmacologic therapies for smoking cessation.
The amended version now appears on our website.